Correction to: Tiotropium/Olodaterol: A Review in COPD

被引：0
|
作者：
Hannah A. Blair
机构：
[1] Springer Nature,
来源：
Drugs | 2019年 / 79卷 / 12期
关键词：
D O I：
10.1007/s40265-019-01172-3
中图分类号：
学科分类号：
摘要：
The article Tiotropium/Olodaterol: A Review in COPD, written by Hannah.
引用
收藏
页码：1365 / 1365
相关论文
共 50 条
  • [31] Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD
    Maltais, Francois
    Aumann, Joseph-Leon
    Kirsten, Anne-Marie
    Nadreau, Eric
    Macesic, Hemani
    Jin, Xidong
    Hamilton, Alan
    O'Donnell, Denis E.
    EUROPEAN RESPIRATORY JOURNAL, 2019, 53 (03)
  • [32] Efficacy of tiotropium/olodaterol on sedentary/active time in COPD patients: VESUTO study
    Minakata, Yoshiaki
    Motegi, Takashi
    Ueki, Jun
    Gon, Yasuhiro
    Seki, Tetsuo
    Anzai, Tatsuhiko
    Nakamura, Shuhei
    Hirata, Kazuto
    Ichinose, Masakazu
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [33] Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers
    Derom, Eric
    Korn, Stephanie
    Hamilton, Alan
    Amatto, Valeria C.
    Zhao, Yihua
    Maltais, Francois
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [34] Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies
    Dave Singh
    Mina Gaga
    Olaf Schmidt
    Leif Bjermer
    Lars Grönke
    Florian Voß
    Gary T. Ferguson
    Respiratory Research, 17
  • [35] Cost-Effectiveness Analysis of Fixed-Dose Tiotropium/Olodaterol versus Tiotropium for COPD Patients in China
    Lan, Ying
    Yang, Nan
    Wang, Yirong
    Yang, Yan
    Xu, Min
    He, Qin
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2023, 18 : 2093 - 2103
  • [36] BENEFITS OF TIOTROPIUM/OLODATEROL OVER TIOTROPIUM AT DELAYING CLINICALLY SIGNIFICANT EVENTS IN PATIENTS WITH COPD CLASSIFIED AS GOLD B
    不详
    THORAX, 2016, 71 : A272 - A273
  • [37] Benefits of tiotropium/olodaterol compared with tiotropium in patients receiving COPD LAMA at baseline: pooled analysis of 4 clinical trials
    Buhl, R.
    Singh, D.
    de la Hoz, A.
    Voss, F.
    Ferguson, G. T.
    PNEUMOLOGIE, 2020, 74 : S69 - S70
  • [38] Benefits of tiotropium/olodaterol compared with tiotropium in patients with COPD receiving only A at baseline: pooled analysis of 4 clinical trials
    Buhl, Roland
    Singh, Dave
    De La Hoz, Alberto
    Voss, Florian
    Ferguson, Gary T.
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [39] Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO®/DYNAGITO® Trials
    Jadwiga A. Wedzicha
    Roland Buhl
    Dave Singh
    Claus F. Vogelmeier
    Alberto de la Hoz
    Wenqiong Xue
    Antonio Anzueto
    Peter M. A. Calverley
    Advances in Therapy, 2020, 37 : 4266 - 4279
  • [40] Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD
    Muruganandan, Sanjeevan
    Jayaram, Lata
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2015, 10 : 1179 - 1189
12345